|
MYH10 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
1.181320E-04 |
| Normal-vs-Stage3 |
3.33066907387547E-15 |
| Normal-vs-Stage4 |
2.41200004413855E-09 |
| Stage1-vs-Stage2 |
9.013800E-01 |
| Stage1-vs-Stage3 |
6.324800E-01 |
| Stage1-vs-Stage4 |
5.945900E-02 |
| Stage2-vs-Stage3 |
7.013200E-01 |
| Stage2-vs-Stage4 |
1.834600E-01 |
| Stage3-vs-Stage4 |
1.588830E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62436730732907E-12 |
| Normal-vs-AfricanAmerican |
1.551570E-04 |
| Normal-vs-Asian |
4.16229999999906E-06 |
| Caucasian-vs-AfricanAmerican |
1.637170E-01 |
| Caucasian-vs-Asian |
2.587800E-01 |
| AfricanAmerican-vs-Asian |
6.812200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.62458935193399E-12 |
| Normal-vs-Female |
1.62458935193399E-12 |
| Male-vs-Female |
3.466000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(41-60Yrs) |
1.11022302462516E-16 |
| Normal-vs-Age(61-80Yrs) |
2.08829953329825E-10 |
| Normal-vs-Age(81-100Yrs) |
1.622500E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.836800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.684400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.449400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
3.465000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.321600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.984600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.856600E-01 |
| Classical-VS-Follicular |
1.66111568944416E-12 |
| Classical-VS-Other |
2.058200E-02 |
| Classical-VS-Normal |
<1E-12 |
| Tall-VS-Follicular |
5.49489999945862E-07 |
| Tall-VS-Other |
7.189500E-02 |
| Tall-VS-Normal |
1.81320003456165E-09 |
| Follicular-VS-Other |
2.877400E-01 |
| Follicular-VS-Normal |
1.900240E-02 |
| Other-VS-Normal |
1.877620E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62481139653892E-12 |
| Normal-vs-N1 |
3.68479999957039E-07 |
| N0-vs-N1 |
2.088300E-02 |
|
|
